INDIA Trends and Developments Contributed by: Pravin Anand, Vaishali Mittal and Gursimran Singh Narula, Anand and Anand
• appellate mechanism – an appeal may be preferred against the adjudicating officer’s decision within 60 days, electronically under Form 33. Conclusion The path of pharmaceutical patent litigation in India, as shown in this chapter, indicates a system that has shifted from uncertainty to greater confidence and better enforcement. Indian courts today are knowl ‑ edgeable, methodical and aware of commercial reali ‑ ties. Patent disputes are no longer seen as theoretical arguments over validity but as high-stakes commer ‑ cial matters with real market impacts. A key aspect of this change is the courts’ ongoing engagement with science, covering small molecules, biologics, biosimilars, and formulation and process patents. The increased use of scientific advisers, structured claim processes and detailed infringement mapping shows a move away from broad reasoning to precise, evidence-based decision-making. At the same time, ongoing discussions about genus and species claims, therapeutic effectiveness and selec ‑ tion inventions indicate that the courts are actively redefining the line between true innovation and unac ‑ ceptable monopoly extension. Another important development is the clear change in the enforcement environment.
The increase in pre-launch and quia timet actions, more careful examination of interim injunctions, and the clear assignment of the burden of proof on defendants together reveal a judiciary that is increas ‑ ingly unwilling to accept speculative patent enforce ‑ ment or casual at-risk generic launches. Patent rights are now viewed as commercial assets rather than just legal privileges, with courts fully aware that disrup ‑ tions during the patent term can lead to lasting market damage. These judicial changes occur alongside regulatory updates, digitisation of patent management, and the easing of penalties for procedural mistakes, all sug ‑ gesting a system that is quicker, more open and better suited to industry needs. In conclusion, Indian phar ‑ maceutical patent litigation has entered a phase that emphasises strategic enforcement, scientific accu ‑ racy and commercial realism. For legal profession ‑ als and the industry, the main question is no longer whether patents will be enforced in India but rather how early, how specifically and how decisively that enforcement will take place.
88 CHAMBERS.COM
Powered by FlippingBook